Skip to content
Open access

Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines

Sep 2026 · International Journal of Molecular Sciences · Vol 27, pp. 8507 · 0 citations · 73 references
Medicine

TL;DR

A comprehensive cross-omics approach was applied to identify a conserved molecular response to CDK4/6 inhibition that warrants future experimental and clinical validation and a panel of highly conserved candidate biomarkers warrants future experimental and clinical validation.

Abstract

Treatment of metastatic breast cancer with CDK4/6 inhibitors in combination with hormone ablation is the current first-line standard of care for this indication, and the therapeutic activity of these inhibitors has been demonstrated in various tumor entities. However, the efficacy of CDK4/6 inhibitor monotherapy is limited and requires combination with suitable additional inhibitors. Delineating the molecular pathways underlying treatment response may provide a rationale for personalized combination therapies that target deregulated pathways upstream of the core signature of response. We applied a comprehensive cross-omics approach to identify a conserved molecular response to CDK4/6 inhibition. Integration of transcriptomic, proteomic, and functional genomic data across multiple cancer models enabled us to refine a previously proposed multi-step model of response to the CDK4/6 inhibitor palbociclib. Initiation of cell-cycle arrest and inhibition of DNA replication is followed by activation of signaling events that suppress mitotic transcriptional programs. The identified panel of highly conserved candidate biomarkers warrants future experimental and clinical validation.

Read PDF

Similar papers

Review Open access Oct 2026

Next-generation CDK inhibitors in HR+/HER2– breast cancer

Cell-cycle dysregulation is a central driver of breast cancer progression and a major therapeutic vulnerability, particularly in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) disease. The clinical success of cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine t...

D. Seriak, J. Kim, G. Shapiro et al. · 0 citations
Open access Sep 2026

Targeting the CDK4-Cyclin D Complex: A New Generation of Selective Kinase Inhibitors for Cancer Therapy

A strategy to identify novel CDK4 inhibitors targeting the CDK4-Cyclin D1 protein-protein interaction, a key determinant of CDK4 activation, and diophenic emerged as the lead candidate, demonstrating consistent antiproliferative activity across multiple GBM and epithelial cancer models.

M. Fuentes-Baile, J. A. Encinar, Salomé Araujo-Abad et al. · 0 citations
Oct 2026

Integrative Multi-Model Analysis Identifies a Core Gene Signature Associated with WEE1 Inhibitor Resistance, the Resistance-Associated Tumor Microenvironment, and Therapeutic Vulnerability in Ovarian Cancer.

BACKGROUND Ovarian cancer is the most lethal gynecological malignancy, and acquired resistance to chemotherapy and targeted therapy is a central cause of treatment failure. The WEE1 inhibitor AZD1775 (adavosertib) has shown clinical activity in ovarian cancer, particularly in tumors with TP53 dysfunction, but acquired...

Chun-Tian Lei, Jia-Qiang Xiong, Yu-Rou Chen et al. · 0 citations
Open access Oct 2026

Multi-omics profiling identifies triciribine as a biomarker-guided antimetabolite therapy for acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) exhibits molecular and metabolic heterogeneity that limits therapeutic efficacy. Although antimetabolites remain central to ALL treatment, determinants of therapeutic sensitivity and resistance remain incompletely understood. Here, we investigated the activity and molecular response l...

Xue-Kang Qi, G. Mermelekas, Ondřej Hodek et al. · 0 citations
Oct 2026

Integrative transcriptomic and network analysis elucidates the multi-target molecular mechanisms of carboplatin in melanoma

Overall, this study identifies key molecular determinants of melanoma progression and provides mechanistic evidence explaining carboplatin’s therapeutic activity through modulation of dysregulated transcriptomic hubs and offers a valuable strategy for biomarker discovery and mechanistic evaluation of clinically used ag...

Mobina Shahriarizade, Seyed Mehdi Ahmadi, Ali Ahmadizad Firouzjaei · 0 citations
Open access Oct 2026

Dual Role of Cx43 in Enhancing CDK4/6 Inhibitor Response and Promoting the Elimination of Therapy-Induced Senescent Tumor Cells

Breast cancer has become the most prevalent malignancy worldwide. A key clinical advance has been the introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), that in combination with endocrine therapy has been a major advance for the treatment of luminal (ER⁺/HER2⁻) breast cancer. CDK4/6i induce cell cycle ar...

P. Carpintero-Fernández, Marta Barturen-Gómez, Vanesa Alvarez et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.